Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeogenFRA:NG2 -0.49%69 EV-to-EBIT is 64.41 as of Aug. 14, 2026, which is 38% above its 10-year median of 46.66. GuruFocus rates FRA:NG2 with a GF Score™ of 69/100 and a GF Value™ of €9.20 (Fairly Valued). The stock has 5 warning signs investors should review. Among 473 Medical Devices & Instruments companies, Neogen ranks worse than 88.79% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Neogen's Enterprise Value is €2,776.8 Mil.
Neogen's EBIT for the trailing twelve months (TTM) ended in May. 2026 was €43.1 Mil. Therefore, Neogen's EV-to-EBIT for today is 64.41.
The historical rank and industry rank for Neogen's EV-to-EBIT or its related term are showing as below:
FRA:NG2'
s EV-to-EBIT Range Over the Past 10 Years
Min: -8.08 Med: 46.66 Max: 269.68
Current: 63.84
During the past 13 years, the highest EV-to-EBIT of Neogen was 269.68. The lowest was -8.08. And the median was 46.66.
FRA:NG2's EV-to-EBIT is ranked worse than 88.79% of 473
companies
in the Medical Devices & Instruments industry
Industry Median: 19.17
vs FRA:NG2: 63.84
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Neogen's Enterprise Value for the quarter that ended in May. 2026 was €2,232.6 Mil.
Neogen's EBIT for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €43.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neogen EV-to-EBIT Related Terms
Neogen EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Neogen's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NG2 vs NVCR, AXGN, UFPT: EV-to-EBIT Comparison
For the Medical Devices subindustry, Neogen's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neogen EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Neogen's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Neogen's EV-to-EBIT falls into.
Neogen's current Enterprise Value is €2,776.8 Mil.
Neogen's EBIT for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €43.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neogen (FRA:NG2) has a EV-to-EBIT of 64.41 as of Aug. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Neogen and its competitors. This is 38% above median its historical median of 46.66. According to the industry distribution chart, Neogen ranks #420 out of 473 companies in the Medical Devices & Instruments industry, placing it in the top 88.8%.
Is Neogen's EV-to-EBIT too high?
Neogen's current EV-to-EBIT of 64.41 is 38% above median its 10-year median of 46.66. The Medical Devices & Instruments industry median EV-to-EBIT is 19.17. Neogen's value of 64.41 is 236% above this industry median. Based on the distribution chart, Neogen ranks #420 out of 473 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Neogen has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neogen's EV-to-EBIT compare to NVCR and AXGN?
According to the Medical Devices & Instruments industry distribution chart, Neogen ranks #420 out of 473 companies for EV-to-EBIT. This places Neogen in the lower half of its industry. The industry median EV-to-EBIT is 19.17. Neogen's value of 64.41 is 236% above this benchmark. While the company's 10-year median is 46.66 vs. the industry median of 19.17, Neogen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.17, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neogen's current EV-to-EBIT of 64.41 is 236% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Neogen and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neogen's current EV-to-EBIT is 64.41, which is 38% above median its own 10-year median of 46.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neogen stock overvalued right now?
Based on GuruFocus' analysis, Neogen (FRA:NG2) is currently considered Fairly Valued. The stock's GF Value™ is €9.20, compared to a current price of €9.79 — trading 6.4% above its estimated fair value. The current EV-to-EBIT is 64.41, which is 38% above median its 10-year median of 46.66 and 236% above the Medical Devices & Instruments industry median of 19.17. Neogen's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Neogen (FRA:NG2), the current EV-to-EBIT is 64.41 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neogen (FRA:NG2) Overvalued in 2026?
Based on GuruFocus' analysis, Neogen stock appears to be overvalued.
The current stock price of €9.79 is trading 6.4% above its estimated GF Value™ of €9.20.
GuruFocus considers Neogen to be Fairly Valued.
Key valuation signals for FRA:NG2:
EV-to-EBIT: 64.41 (38% above median its 10-year median of 46.66)
GF Value™: €9.20 vs. price of €9.79 (6.4% above fair value)
Industry Position: 236% above the Medical Devices & Instruments median (#420 of 473)
No single metric tells the full story. See the FRA:NG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
69GF Score
Get the complete analysis for FRA:NG2
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NG2 has been successfully added to your 
